Lyon wrote:I've never mentioned it to anyone but if Jamie's MS progressed, Cladribine is what I'm most interested in of the options to be available in the near future.
Her neuro in the Tovaxin clinical trial was trained by Kurtzke at Georgetown and the first thing she told us, almost seemed to be bragging, was that, of her patients on Copaxone she had never had one progress to the wheelchair. That always seemed impressive for some reason. I should have asked her what the hell it meant exactly.
And it has a long safety record too. They also sometimes use it alongside Novantrone for aggressive MS, starting with Novantrone infusions then follow up and stay on Copaxone (I think that's how I recall it.)
The only bad thing for me is the skin dents but I can live with those for another year or two if I have to.
I have more fat than the last time I took it so maybe that won't be a problem as much this time.
Take care, Ewizabeth Previously Avonex, Rebif & Copaxone RRMS ~Tysabri, 31 infusions, ended 9/09. Starting Copaxone 12/09, waiting for Cladribine to be approved in 2010.